INTEGRATED BIOPHARMA INC.

INBP

HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025. Revenue for the quarter ended June 30, 2025 was $14.2 million compared to $12.7 million for the quarter ended June 30, 2024, an increase of $1.5 million or 11.8%.

HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025. Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%.

HILLSIDE, NJ / ACCESS Newswire / February 13, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2024. Revenue for the quarter ended December 31, 2024 was $12.6 million compared to $11.5 million for the quarter ended December 31, 2023, an increase of $1.1 million or 9.6%.

HILLSIDE, NJ / ACCESSWIRE / November 13, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024. Revenue for the quarter ended September 30, 2024 was $13.6 million compared to $12.9 million for the quarter ended September 30, 2023, an increase of $0.7 million or approximately 5.4%.

HILLSIDE, NJ / ACCESSWIRE / September 20, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2024. Revenue for the quarter ended June 30, 2024 was $12.7 million compared to $13.0 million for the quarter ended June 30, 2023, a decrease of $0.3 million or 2.3%.

HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million.

HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million compared to $12.3 million for the quarter ended December 31, 2022, a decrease of $0.8 million or 6.5%.